NTRA

Natera, Inc.

$281.27 -2.53 (-0.89%) At close · Jul 7

Market Cap

$40.28B

143,215,382

Equibles Rating blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol High

Market backdrop VIX 16.9 · calm Equity put/call 0.86

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +33%

above

Price vs 50-day avg +27%

above

RSI (14) 77

overbought

MACD trend Positive

52-week position 96%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +31%

trailing

6-month return +19%

trailing

YTD return +23%

this year

Relative strength +12%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $221 › 200d $212 — 50d above 200d

Institutional flow Accumulating

27 of 762 funds reported for Jun 30 · net +206.5K sh shares · +6 new

Insider flow Distributing

Net -$38.1M over 90 days · 100% sells

Short interest Rising

3.01% of float · ▲ +19.4% MoM · 4.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

762 holders — near 3-yr high, broad support

Squeeze score 69

elevated · 0–100

Fundamentals

Strong

Revenue growth −3%

Y/Y

EPS growth +1%

Y/Y

Free cash flow $109.1M

Balance sheet $183.1M

net cash

Quant / Vol

risk profile

High

Volatility 43%

annualized · 1-yr

Max drawdown −28%

past year

ATR 4.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next

Next earnings call

Aug 6, 2026 Est · unconfirmed · in 4 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 8, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Guidance & track record what management promised — and delivered

Latest guidance · from the 8-K filed May 7, 2026

Total revenue · 2026 Initiated $2.74B – $2.82B

prior FY $2.31B midpoint +20.5% Y/Y

Gross margin · 2026 Initiated 64% – 66%

Selling, general and administrative costs · 2026 Initiated $1.13B – $1.23B

Research and development costs · 2026 Initiated $800M – $900M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 2 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+33% Bullish

Price vs 50-day avg

+27% Bullish

RSI (14)

77 Bearish

MACD trend

Positive Bullish

52-week position

96% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $221 › 200d $212 — 50d above 200d

Institutional flow Accumulating

27 of 762 funds reported for Jun 30 · net +206.5K sh shares · +6 new

Insider flow Distributing

Net -$38.1M over 90 days · 100% sells

Short interest Rising

3.01% of float · ▲ +19.4% MoM · 4.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

762 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $132 Now $281 · 96% 52-wk high $288

vs 200-day avg +33% vs 50-day avg +27%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
Oncology tests processed	258,900	Q1 2026	—

Tests accessioned	999,200	Q1 2026	—

Tests processed	1,013,600	Q1 2026	—

Tests reported in our laboratory	918,100	Q1 2026	—
clinical oncology units processed	249K	Q1 call	—
Signatera ASP	$1,250	Q1 call	—
units delivered in a single quarter	1M	Q1 call	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Diagnostics & Research — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
NTRA Natera, Inc. this stock	$40.28B	+22.8%	-2.8%	—	3.0%
TMO Thermo Fisher Scientific Inc.	$189.58B	-11.9%	+0.4%	28.0	1.2%
DHR Danaher Corp /De/	$135.02B	-14.8%	+8.5%	36.8	1.6%
IDXX Idexx Laboratories Inc /De	$43.83B	-17.9%	+10.4%	40.9	2.7%
WAT Waters Corp /De/	$36.81B	-1.3%	+7.0%	—	4.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

766

% held: 90.3%
Reported: 27 of 762
Top holder: JPMORGAN CHASE & CO

Held Float

View

Held by Funds

Fund positions

670

View

Short & Settlement

Short Interest Rising

Shares short

4.3M

Days to cover: 4.0d
Change: +700.0K sh

View

Short Volume

Short vol %

35%

As of: Jul 8, 2026

Short Total

View

Fails to Deliver

FTD shares

15.3K

Value: $3.4M
As of: Jun 12, 2026

View

Off-Exchange

Off-exchange %

44.8%

Week of: Jun 15, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$38.1M

Buyers / Sellers: 0 / 9

Buyers Sellers

View

Congressional Trades Buy

Member

Josh Gottheimer

Amount: $1.0K–$15.0K
Traded: Sep 22, 2025

View

Financials

Revenue (FY)

$2.3B

Net income (FY): $-208.2M
EPS diluted: $-1.52

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 6, 2026
This year: 12

View

Proposed Sales

Value

$280.0K

Shares: 1.0K
Filed: Jul 6, 2026

View

Earnings & Events

Earnings Calls

Last call

Jun 8, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
NTRA	+3.3%	+30.6%	+19.5%	+3.6%	+22.8%
SPY	+0.9%	+1.4%	+7.6%	+0.1%	+9.7%
vs SPY	+2.4%	+29.3%	+11.9%	+3.5%	+13.1%

Key facts CIK 1604821 CUSIP 632307104 13F (30d) 30 filings 27 filers Visit website Investor relations

NTRA

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance